Substance / Medication

Tizanidine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient.
Kitabata Yukiko, Orita Hikari, Kamimura Motohiro et al. · Ther Apher Dial · 2005
PMID: 15828911Case Report
Formulation Optimization and Characterization of Tizanidine Hydrochloride-loaded Gold Nanoparticles Using Quality by Design Approach.
Kamble Milind Dharmraj, Gaikwad Mahesh, Marathe Rajendra et al. · Pharm Nanotechnol · 2025
PMID: 38685788Other
Intranasal spray of cubosomal tizanidine hydrochloride for brain targeting:andcharacterisation.
Thakkar Hetal, Modi Bhumi, Patel Brijesh · J Microencapsul · 2023
PMID: 37129532Other
Development and Stability Control of Pediatric Oral Tizanidine Hydrochloride Formulations for Hospital Use.
Gobetti Caren, Balsan Maria Eduarda, Ayres Márcio Vinícius et al. · AAPS PharmSciTech · 2020
PMID: 32729029Other
Formulation of tizanidine hydrochloride-loaded provesicular system for improved oral delivery and therapeutic activity employing a 2full factorial design.
Mohsen Amira Mohamed, El-Hashemy Hadeer Ahmed, Salama Abeer et al. · Drug Deliv Transl Res · 2023
PMID: 35927549PreclinicalFull text (PMC)
Microneedle-Mediated Transdermal Delivery of Tizanidine Hydrochloride.
Thakkar Hetal, Pandya Kartik, Patel Brijesh · Methods Mol Biol · 2020
PMID: 31435926Preclinical
Optimization of Microemulgel for Tizanidine Hydrochloride.
Jagdale Swati, Brahmane Sujata, Chabukswar Anuruddha · Antiinflamm Antiallergy Agents Med Chem · 2020
PMID: 30854978PreclinicalFull text (PMC)
Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization.
Khalil Rawia M, Abdelbary Ahmed, Kocova El-Arini Silvia et al. · J Liposome Res · 2019
PMID: 30221568Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tizanidine hydrochloride (substance)
SNOMED CT
108462003
UMLS CUI
C0771735

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.